What is the Organoid Sciences Co., Ltd. stock price forecast?

Organoid Sciences Co., Ltd. is currently trading at ₩11,870. View real-time AI analysis on Alpha Lenz.

What is Organoid Sciences Co., Ltd. insider trading activity?

View the latest insider trading data for Organoid Sciences Co., Ltd. on Alpha Lenz.

What is Organoid Sciences Co., Ltd.'s P/E ratio?

Organoid Sciences Co., Ltd.'s P/E ratio is -5.1.

Organoid Sciences Co., Ltd.

KRX · 476040

₩11,870-240(-1.98%)Market closed

Ask about Organoid Sciences Co., Ltd.'s future dividend policy...

Alpha Chat Insight

“Organoid Sciences Co., Ltd. trades at a P/E of -5.1 (undervalued) with modest ROE of -76.9%. 3Y revenue CAGR of 76.4% highlights clear growth momentum.”

Ask for details →

Company Overview

Organoid Sciences Co., Ltd. is a South Korean biotechnology company recognized for its pioneering work in organoid-based drug development. Founded in 2018 and headquartered in Seongnam, the company specializes in utilizing organoids—miniaturized and simplified versions of organs grown in vitro—to develop innovative treatments for diseases that are otherwise considered incurable. Organoid Sciences is particularly active in the realms of drug discovery, screening, and regenerative medicine, supporting both therapeutic development and advanced research applications. As part of this focus, the company develops regenerative therapies and provides cutting-edge solutions to accelerate the creation of new pharmaceuticals targeting complex and unmet medical needs. By leveraging organoid technology, Organoid Sciences is positioned at the intersection of biotechnology, medical research, and pharmaceutical innovation, contributing significantly to advancements in personalized medicine and disease modeling within the healthcare sector.

CEO유종만

Websitehttps://organoidrx.com

SectorHealthcare

IndustryBiotechnology

Company Statistics

FY 2025

Profile

₩78,172,971,200Market Cap

₩2,406,581,880Revenue

6.59MShares Out

0Employees

Margins

100.00%Gross

-593.30%EBITDA

-673.16%Operating

-654.00%Pre-Tax

-654.00%Net

Valuation

-5.09P/E

3.17P/B

32.48EV/Sales

-5.61EV/EBITDA

-4.90P/FCF

Growth (CAGR)

76.43%Rev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-49.90%ROA

-76.89%ROE

-48.74%ROIC

Financial Health

₩5,237,763,440Cash & Cash Equivalents

₩7,111,788,510Net Debt

49.71%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Organoid Sciences Co., Ltd. trades at a P/E of -5.1 (undervalued) with modest ROE of -76.9%. 3Y revenue CAGR of 76.4% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Organoid Sciences Co., Ltd. (ticker: 476040) is a company listed on KRX in the Healthcare sector (Biotechnology). Market cap is $78.2B.

The current price is ₩11,870 with a P/E ratio of -5.09x and P/B of 3.17x.

ROE is -76.89% and operating margin is -673.16%. Annual revenue is $2.4B.